Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (NCT07890636) titled 'Adebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLC' on Oct. 16.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Ruijin Hospital

Condition: Lung Neoplasm Malignant

Intervention: Drug: Adebrelimab

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: October 20, 2026

Target Sample Size: 64

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07890636

Disclaimer: Curated by HT Syndication....